Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Shock. 2023 Dec 1;60(6):746-752. doi: 10.1097/SHK.0000000000002193. Epub 2023 Aug 4.
Background: Septic shock is a distributive shock with decreased systemic vascular resistance and MAP. Septic shock contributes to the most common causes of death in the intensive care unit (ICU). Current guidelines recommend the use of norepinephrine as the first-line vasopressor, whereas adrenergic agonists and vasopressin analogs are also commonly used by physicians. To date, very few studies have synthetically compared the effects of multiple types of vasoactive medications. The aim of this study was to systemically evaluate the efficacy of vasoactive agents both individually and in combination to treat septic shock. Methods: The PubMed, MEDLINE, Embase, Web of Science, and Cochrane Central Register for Controlled Trials (CENTRAL) were searched up to May 12, 2022, to identify relevant randomized controlled trials. A network meta-analysis was performed to evaluate the effect of different types of vasopressors. The primary outcome was 28-day all-cause mortality. The secondary outcome was the ICU length of stay. Adverse events are defined as any undesirable outcomes, including myocardial infarction, cardiac arrhythmia, peripheral ischemia, or stroke and cerebrovascular events. Findings: Thirty-three randomized controlled trials comprising 4,966 patients and assessing 8 types of vasoactive treatments were included in the network meta-analysis. The surface under the cumulative ranking curve provided a ranking of vasoactive medications in terms of 28-day all-cause mortality from most effective to least effective: norepinephrine plus dobutamine, epinephrine, vasopressin, terlipressin, norepinephrine, norepinephrine plus vasopressin, dopamine, and dobutamine. Dopamine was associated with a significantly shorter ICU stay than norepinephrine, terlipressin, and vasopressin, whereas other vasoactive medications showed no definite difference in ICU length of stay. Regarding adverse events, norepinephrine was associated with the highest incidences of myocardial infarction and peripheral ischemia. Dopamine was associated with the highest incidence of cardiac arrhythmia. Epinephrine and terlipressin were associated with the highest incidences of myocardial infarction and peripheral ischemia. Interpretation: The results of this network meta-analysis suggest that norepinephrine plus dobutamine is associated with a lower risk of 28-day mortality in septic shock patients than other vasoactive medications, and the use of dopamine is associated with a higher risk of 28-day mortality due to septic shock than norepinephrine, terlipressin, and vasopressin.
感染性休克是一种分布性休克,伴有全身血管阻力和平均动脉压降低。感染性休克是重症监护病房(ICU)中最常见的死亡原因之一。目前的指南建议使用去甲肾上腺素作为一线血管加压药,而儿茶酚胺类药物和血管加压素类似物也被医生广泛使用。迄今为止,很少有研究综合比较多种血管活性药物的效果。本研究旨在系统评估单独使用和联合使用血管活性药物治疗感染性休克的疗效。
检索 PubMed、MEDLINE、Embase、Web of Science 和 Cochrane 对照试验中心注册库(CENTRAL),截至 2022 年 5 月 12 日,以确定相关的随机对照试验。进行网络荟萃分析以评估不同类型血管加压药的效果。主要结局为 28 天全因死亡率。次要结局为 ICU 住院时间。不良事件定义为任何不良结果,包括心肌梗死、心律失常、外周缺血或卒中和脑血管事件。
纳入了 33 项随机对照试验,包括 4966 名患者,评估了 8 种血管活性治疗方法的网络荟萃分析。累积排序曲线下面积提供了血管活性药物治疗 28 天全因死亡率的排序,从最有效到最不有效依次为:去甲肾上腺素加多巴酚丁胺、肾上腺素、血管加压素、特利加压素、去甲肾上腺素、去甲肾上腺素加血管加压素、多巴胺和多巴酚丁胺。与去甲肾上腺素、特利加压素和血管加压素相比,多巴胺与 ICU 住院时间更短相关,而其他血管活性药物在 ICU 住院时间上无明显差异。关于不良事件,去甲肾上腺素与心肌梗死和外周缺血发生率最高相关。多巴胺与心律失常发生率最高相关。肾上腺素和特利加压素与心肌梗死和外周缺血发生率最高相关。
本网络荟萃分析的结果表明,与其他血管活性药物相比,去甲肾上腺素加多巴酚丁胺治疗感染性休克患者 28 天死亡率较低,而使用多巴胺与感染性休克患者 28 天死亡率较高相关,高于去甲肾上腺素、特利加压素和血管加压素。